13196-11-7

Usage

Uses

Used in Fragrance Industry:
1-Benzofuran-6-ol is used as a fragrance ingredient for its floral scent, adding pleasant aromas to various personal care products and household items.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 1-Benzofuran-6-ol is utilized in the manufacturing process of certain medications, contributing to the development of new therapeutic agents.
Used as a Solvent:
This aromatic compound also serves as a solvent in various chemical processes, facilitating reactions and aiding in the production of different substances.
Used as an Intermediate in Organic Synthesis:
1-Benzofuran-6-ol is employed as an intermediate in organic synthesis, playing a crucial role in the synthesis of complex organic compounds and contributing to the advancement of chemical research and development.

InChI:InChI=1/C8H6O2/c9-7-2-1-6-3-4-10-8(6)5-7/h1-5,9H

Upstream product

• 334022-87-6 6-hydroxybenzofuran-2-carboxylic acid 
• 271-89-6 1-benzofurane 
• 50551-63-8 6-methoxybenzofuran 
• 96853-42-8 4-(2-Nitroethyl)benzene-1,3-diol 
• 1020947-92-5 6-hydroxy-2,3-dihydrobenzofuran-3-ol 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 92964-98-2 6-benzyloxy-benzofuran-2-carboxylic acid 
• 52085-14-0 4-benzoxy-salicylaldehyde 
• 906448-92-8 6-hydroxy-benzofuran-2-carboxylic acid ethyl ester 
• 6272-26-0 6-hydroxybenzofuran-3-one 
• 60-29-7 diethyl ether 
• 108-46-3 recorcinol 
• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 76322-06-0 2-ethoxycarbonylmethoxy-4-methoxybenzaldehyde 

Downstream Products

• 113228-33-4 2-(3,5-Bis-triisopropylsilanyloxy-phenyl)-benzofuran-6-ol 
• 112768-54-4 6-hydroxybenzofuran t-butyldiphenylsilyl ether 
• 227752-25-2 trifluoromethanesulfonic acid benzofuran-6-yl ester 
• 14159-13-8 5-methyl-7H-furan[3,2-g]benzopyran-7-one 
• 66486-61-1 4-phenyl-psoralen 
• 66-97-7 psoralen 
• 957146-68-8 6-[2-(Difluoromethoxy)-4-(trifluoromethyl)phenoxy]-1-benzofuran 
• 957146-73-5 6-[(3-iodobenzyl)oxy]-1-benzofuran 
• 957146-64-4 6-[2-chloro-4-(trifluoromethyl)phenoxy]-1-benzofuran 
• 1056942-26-7 C₁₄H₉IO₂ 
• 123297-88-1 benzofuran-6-carboxaldehyde 
• 56317-21-6 moracin M 
• 69120-06-5 moracin C 
• 134804-66-3 6-hydroxy-4-methoxy-2-phenylbenzofuran 

Relevant academic research and scientific papers

PD-1/PD-L1 small-molecule inhibitor and preparation method and application thereof

The invention discloses a PD-1/PD-L1 small-molecule inhibitor and a preparation method and application thereof. Specifically, the invention discloses a compound with the structure shown in the formulaL, a stereoisomer or a tautomer thereof, or pharmaceutically acceptable salts or hydrates or solvates thereof, and please see the specification for specific definitions. The compound has excellent effects for restraining PD-1/PD-L1. Please see the specification for the formula.

Palladium-Catalyzed Regioselective C-2 Arylation of Benzofurans with N′-Acyl Arylhydrazines

A novel ligand-free palladium-catalyzed C-2 arylation of benzofurans has been developed using N′-acyl arylhydrazines as the coupling partners and TEMPO as an oxidant. This protocol features a wide functional-group tolerance and highly regioselective products with good to excellent yields.

HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.

An improved and scale-up synthesis of 6-hydroxybenzofuran

An optimized process for the preparation of 6-hydroxybenzofuran is described. This process consists of three steps: the reaction of 2-hydroxy-4-methoxybenzaldehyde with chloroacetic acid, the formation of the 6-methoxybenzofuran in acetic anhydride, and t

Concise synthesis of 6-cyanobenzo[ b ]furan, a useful building block

A new three-step synthesis of 6-cyanobenzo[b]furan (6) was developed, starting from commercially available 6-hydroxybenzo[b]furan-3-one (18). Key steps in this process were the first step, which was the reductive dehydration of 18 to produce 6-hydroxybenzo[b]furan (19), and the last step, which converted the aryl triflate 20 to the aryl cyanide 6 in a palladium-catalyzed cross-coupling protocol. Overall yield for this new synthesis was 49%.

LFA-1 INHIBITOR AND POLYMORPH THEREOF

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA -1 mediated diseases are also disclosed.

Synthetic models related to methoxalen and menthofuran-cytochrome P450 (CYP) 2A6 interactions. Benzofuran and coumarin derivatives as potent and selective inhibitors of CYP2A6

Human microsomal cytochrome P450 (CYP) 2A6 contributes extensively to nicotine detoxication but also activates tobacco-specific procarcinogens to mutagenic products. We prepared a series of benzofuran and coumarin derivatives that have inhibitory effects on the activity of human CYP2A6. The reported compounds methoxalen and menthofuran had potent inhibitory effects on the activity of CYP2A6 with IC50 values of 0.47 μM and 1.27 μM, respectively. Synthetic benzofuran (4-methoxybenzofuran: IC50=2.20 μM) and coumarin (5-methoxycoumarin: IC50=0.13 μM and 6-methoxycoumarin: IC50=0.64 μM) derivatives, which have more selective effects than those of methoxalen and menthofuran, exhibited comparable activities against CYP2A6. These compounds can be used as a lead compounds in the design of CYP2A6 inhibitor drugs to reduce smoking and tobacco-related cancers.

Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye

LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.

Toluene dioxygenase-catalyzed cis-dihydroxylation of benzo[b]thiophenes and benzo[b]furans: Synthesis of benzo[b]thiophene 2,3-oxide

Enzymatic cis-dihydroxylation of benzo[b]thiophene, benzo[b]furan and several methyl substituted derivatives was found to occur in both the carbocyclic and heterocyclic rings. Relative and absolute configurations and enantiopurities of the resulting dihydrodiols were determined. Hydrogenation of the alkene bond in carbocyclic cis-dihydrodiols and ring-opening epimerization/reduction reactions of heterocyclic cis/trans-dihydrodiols were also studied. The relatively stable heterocyclic dihydrodiols of benzo[b]thiophene and benzo[b]furan showed a strong preference for the trans configuration in aqueous solutions. The 2,3-dihydrodiol metabolite of benzo[b]thiophene was utilized as a precursor in the chemoenzymatic synthesis of the unstable arene oxide, benzo[b]thiophene 2,3-oxide.

Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study

Psoralen (1a) was found to be a specific and potent antimicrobial lead against Helicobacter pylori (H. pylori) from a traditional Chinese medicine (TCM) in the bioassay directed isolation. A series of structurally diverse analogues of 1a were thus designed and synthesized to improve the antimicrobial potency, some of which showed more potent activities than the lead compound (1a) against H. pylori. Among them, compound 25a is 16-fold stronger (MIC = 0.39 μg/mL) than 1a (MIC = 6.25 μg/mL), and is even potent than the positive control metronidazole (MIC = 0.50 μg/mL). The in vitro antimicrobial activities against H. pylori of these structurally diverse analogues based on the scaffold of 1a have also led to an outline of structure-activity relationship.